A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2220 participants.

Also called NCT01516541

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,220 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01516541
  • EudraCT 2011-001891-21
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Canada, China, Czechia, Denmark, France, Hungary, Mexico, Netherlands, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01516541. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2012-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
Condition
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Intervention (Other)
Background care
Intervention (Drug)
Placebo
Intervention (Drug)
dalcetrapib
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct01516541
Content hash
562fb53e0259fd9470bd568b4d42ec9293c397609bcc11a4a0ffd3cba39bea2f